Castle Biosciences (CSTL) Revenue & Revenue Breakdown
Castle Biosciences Revenue Highlights
Latest Revenue (Y)
$219.79M
Latest Revenue (Q)
$85.78M
Main Segment (Y)
Dermatologic
Castle Biosciences Revenue by Period
Castle Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $219.79M | 60.38% |
| 2022-12-31 | $137.04M | 45.65% |
| 2021-12-31 | $94.08M | 50.18% |
| 2020-12-31 | $62.65M | 20.79% |
| 2019-12-31 | $51.87M | 127.62% |
| 2018-12-31 | $22.79M | 65.67% |
| 2017-12-31 | $13.75M | - |
Castle Biosciences generated $219.79M in revenue during NA 2023, up 60.38% compared to the previous quarter, and up 964.59% compared to the same period a year ago.
Castle Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $85.78M | -1.40% |
| 2024-06-30 | $87.00M | 19.22% |
| 2024-03-31 | $72.97M | 10.37% |
| 2023-12-31 | $66.12M | 7.52% |
| 2023-09-30 | $61.49M | 22.65% |
| 2023-06-30 | $50.14M | 19.27% |
| 2023-03-31 | $42.04M | 9.65% |
| 2022-12-31 | $38.34M | 3.59% |
| 2022-09-30 | $37.01M | 6.24% |
| 2022-06-30 | $34.84M | 29.74% |
| 2022-03-31 | $26.85M | 7.24% |
| 2021-12-31 | $25.04M | 6.66% |
| 2021-09-30 | $23.48M | 3.15% |
| 2021-06-30 | $22.76M | -0.24% |
| 2021-03-31 | $22.81M | 31.87% |
| 2020-12-31 | $17.30M | 13.68% |
| 2020-09-30 | $15.22M | 19.68% |
| 2020-06-30 | $12.71M | -27.00% |
| 2020-03-31 | $17.42M | -1.23% |
| 2019-12-31 | $17.64M | 19.36% |
| 2019-09-30 | $14.77M | 37.59% |
| 2019-06-30 | $10.74M | 23.19% |
| 2019-03-31 | $8.72M | -23.78% |
| 2018-12-31 | $11.44M | 208.10% |
| 2018-09-30 | $3.71M | -6.73% |
| 2018-06-30 | $3.98M | 8.77% |
| 2018-03-31 | $3.66M | - |
Castle Biosciences generated $85.78M in revenue during Q3 2024, up -1.40% compared to the previous quarter, and up 171.09% compared to the same period a year ago.
Castle Biosciences Revenue Breakdown
Castle Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Dermatologic | $183.38M | $124.81M | $85.75M |
| Service, Other | - | $12.23M | $8.33M |
Latest
Castle Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Dermatologic (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermatologic | $65.06M | $68.83M | $59.33M | $53.28M | $51.15M | $43.03M | $35.91M | $34.65M | $33.92M | $31.90M | $24.34M |
| Service, Other | - | - | - | - | - | - | - | $3.69M | $3.09M | $2.94M | $2.51M |
Latest
Castle Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Dermatologic (100.00%).
Castle Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FONR | FONAR | $102.88B | $25.94M |
| NTRA | Natera | $1.08B | $439.76M |
| GH | Guardant Health | $563.95M | $177.24M |
| BNR | Burning Rock Biotech | $537.43M | $125.62M |
| TWST | Twist Bioscience | $312.97M | $81.46M |
| CDNA | CareDx | $280.32M | $82.88M |
| CSTL | Castle Biosciences | $219.79M | $85.78M |
| PSNL | Personalis | $73.48M | $22.58M |
| STIM | Neuronetics | $71.35M | $16.45M |
| XGN | Exagen | $52.55M | $15.06M |
| BDSX | Biodesix | $49.09M | $18.15M |
| ENZ | Enzo Biochem | $31.91M | $6.21M |
| SERA | Sera Prognostics | $306.00K | $24.00K |